¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inspiratory triggering response time"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • visual evoked response
    ½Ã°¢À¯¹ß¹ÝÀÀ
  • withdrawal response
    ±Ý´Ü¹ÝÀÀ
  • arm-to-retina circulation time
    ÆÈ¸Á¸·¼øÈ¯½Ã°£
  • atrioventricular conduction time
    ¹æ½ÇÀüµµ½Ã°£
  • acquisition time
    ȹµæ½Ã°£
  • activated coagulation time
    Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • bleeding time
    ÃâÇ÷½Ã°£
  • bleeding time test
    ÃâÇ÷½Ã°£°Ë»ç
  • breath holding time
    ¼ûÂü´Â½Ã°£, È£ÈíÁßÁö½Ã°£
  • circulation time
    ¼øÈ¯½Ã°£
  • clot retraction time
    ÇǶ±µÞ´ç±è½Ã°£, Ç÷º´¼öÃà½Ã°£
  • clotting time
    ÀÀ°í½Ã°£
  • coagulation time
    ÀÀ°í½Ã°£
  • colonic transit time
    ´ëÀåÅë°ú½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • secondary immune response
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • sensitization response
    ¹Î°¨¹ÝÀÀ
  • shortening response
    ´ÜÃà¹ÝÀÀ
  • startle response
    ³î¶÷¹ÝÀÀ
  • stereotyped response
    ÀÚµ¿¹Ýº¹¹ÝÀÀ, »óµ¿¹ÝÀÀ
  • subthreshold response
    ¹®ÅιعÝÀÀ
  • traction response
    ´ç±è¹ÝÀÀ
  • triple response reaction
    (¢¡triple skin reaction) »ïÁßÇǺιÝÀÀ
  • unconditioned response
    ¹«Á¶°Ç¹ÝÀÀ
  • visual evoked response
    ½Ã°¢À¯¹ß¹ÝÀÀ
  • whole response
    Àü¹ÝÀÀ
  • withdrawal response
    öȸ¹Ý»ç, ±Ý´Ü¹ÝÀÀ
  • soluble immune response suppressor
    °¡¿ë¸é¿ª¹ÝÀÀ¾ïÁ¦ÀÎÀÚ
  • acquisition time
    ȹµæ½Ã°£
  • activated coagulation time
    Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • TOF (time of flight)
    È帧 ½Ã°£ TOF(Ƽ¿À¿¡ÇÁ), À¯Ã¼ ¼Óµµ °­?
  • acquisition time
    ȹµæ ½Ã°£
  • activated clotting time
    Ȱ¼ºÈ­ÀÀ°í½Ã°£
  • activated coagulation time(ACT)
    Ȱ¼º Ç÷¾× ÀÀ°í½Ã°£
  • activated coagulation time=ACT
    Ȱ¼ºÈ­ ÀÀ°í½Ã°£
  • activated partial prothrombin time
    Ȱ¼º ºÎºÐÇÁ·ÎÆ®·Òºó½Ã°£
  • activated partial thromboplastin time
    Ȱ¼º ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • activated partial thromboplastin time =aPTT
    Ȱ¼ºÈ­ ºÎºÐ Æ®·Òº¸ÇÃ¶ó½ºÆ¾ ½Ã°£
  • appearance time
    ÃâÇö½Ã°£(õóúÞãÁÊà) ¼øÈ¯(âàü») .
  • area under the concentration-time curve : AUC
    Ç÷Áß(¾à¹°)³óµµ°î¼±ÇϸéÀû.
  • arm to tongue time test
    ÆÈÇô¼øÈ¯½Ã°£½ÃÇè
  • arm-to-retina circulation time
    ÆÈ¸Á¸·¼øÈ¯½Ã°£, ¿Ï-¸Á¸·¼øÈ¯½Ã°£
  • gastric emptying time
    À§(êÖ)(³»¿ë(Ò®é»))¹èÃâ½Ã°£(ÛÉõóãÁÊà).
  • gastric emptying time
    À§(³»¿ë)¹èÃâ½Ã°£.
  • generation time =doubling t.
    ¼¼´ë½Ã°£(á¦ÓÛãÁÊà), ¹èÀ§½Ã°£(ÛÃêÈãÁÊà), ¼¼´ë±â(á¦ÓÛÑ¢).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • frenquency response curve
    Á֯ļö ¹ÝÀÀ°î¼±
  • galvanic skin response =GSR
    Àü±âÇǺιÝÀÀ(ï³Ñ¨ù«Ý±Úãëë).
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀ û·Â°Ë»ç
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
  • ideosyncratic drug response
    ƯÀ̼º ¾à¹° ¹ÝÀÀ
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ.
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦<--¾ï¾Ð>
  • immune response, primary
    ÀÏÂ÷¸é¿ª¹ÝÀÀ
  • immune response, secondary
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • immunologic response
    ¸é¿ª¹ÝÀÀ.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
MLR mean length response; middle latency response; mixed lymphocyte reaction
PR by way of the rectum [Lat. per rectum]; far point [of accommodation] [Lat. punctum remotum]; palindr...
RVR reduced vascular response; renal vascular resistance; repetitive ventricular response; resistance to...
SER sebum excretion rate; sensitizer enhancement ratio; sensory evoked response; service; smooth endopla...
SIRS soluble immune response suppressor; Structured Interview of Reported Symptoms; systemic inflammatory...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
ASR Acoustic startle response
ACT Activated Coagulation Time
APTT Activated Partial Thromboplastin Time
AT Activation time
APR Acute Phase Response
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • time gain control
    ½Ã°£ °ÔÀÎ Á¶Àý
  • time lag
    Áöü ½Ã°£
  • time of death
    »ç¸Á ½Ã°¢
  • time of flight
    È帧 ½Ã°£, À¯Ã¼ ¼Óµµ °­Á¶
  • time of flight phenomenon
    À¯Ã¼ ¼Óµµ °­Á¶ Çö»ó
  • time sharing
    ½Ã°£ °øÀ¯, ½ÃºÐÇÒ
  • time weighted average concentration
    ½Ã°£ °¡Áß Æò±Õ ³óµµ
  • transverse relaxation time
    ȾÃà ÀÌ¿Ï ½Ã°£
  • whole blood clot lysis time
    ÀüÇ÷ Ç÷º´ À¶ÇØ ½Ã°£
  • working time
    ÀÛ¾÷½Ã°£
    ÀÓ»óÀûÀ¸·Î ÀλóÀÌ ±¸°­ ³»¿¡ ÀåÂøµÇ±â Àü±îÁö È¥ÇÕÇÏ°í Æ®·¹ÀÌ¿¡ ´ã¾Æ ±¸°­ ³»¿¡ ÀåÂøÇϴµ¥ ÇÊ¿äÇÑ ÃÖ´ëÇÑÀÇ ½Ã°£.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
blood circulation time Determination of the shortest time interval between the injection of a substance in the vein and its arrival at some distant site in sufficient concentration to produce a recognizable end result. It represents approximately the inverse of the average velocity of blood flow between two points.
(12 Dec 1998)
P-A conduction time See: atrioventricular conduction.
(05 Mar 2000)
generation time <cell biology> Time taken for a cell population to double in numbers and thus equivalent to the average length of the cell cycle.
(18 Nov 1997)
reaction time The time from the onset of a stimulus until the organism responds.
(12 Dec 1998)
real-time ultrasonography Rapid serial ultrasound images produced using a phased array or scanning transducer; produces a video display of organ motion, such as heart valve or foetal motion.
(05 Mar 2000)
recognition time The interval between the application of a stimulus and the recognition of its nature.
(05 Mar 2000)
partial thromboplastin time Test of the intrinsic (factors viii, ix, xi, and xii) and common (fibrinogen, prothrombin, factors v and x) pathways of coagulation in which a mixture of plasma and phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides) is recalcified and the time required for the appearance of fibrin strands measured. Activation may be provided by contact with the glass tube or exposure to activators (e.g., ellagic acid, particulate silicates such as diatomaceous earth or kaolin) before addition of the calcium chloride. It is used as a screening test and to monitor heparin therapy.
(12 Dec 1998)
relaxation time Time taken for a system to return to the resting or ground state or a new equilibrium state following perturbation. Often used in context of receptor systems that have a refractory period after responding and then relax to a competent state. Can be used more precisely to mean the time for a system to change from its original equilibrium value to 1/e of this original value.
(18 Nov 1997)
median time to elimination <pharmacology> The time it takes one half of a drug to be eliminated from the body.
(09 Oct 1997)
repetition time In magnetic resonance imaging, the time between repetitions of the pulse sequence.
(05 Mar 2000)
rise time The time required for a pulse or echo to rise from 10% to 90% of its peak amplitude.
(05 Mar 2000)
P-H conduction time See: atrioventricular conduction.
(05 Mar 2000)
running time The time during which an activity (e.g., chromatography development) occurs.
(05 Mar 2000)
Russell's viper venom clotting time A clotting time determination performed on citrated platelet-poor plasma using Russell's viper venom as an activating agent. This allows activation of factor X directly without the need for other coagulation factors and is used to confirm factor X defects.
See: Stypven time test.
(05 Mar 2000)
circulation time The time taken for the blood to pass through a given circuit of the vascular system, e.g., the pulmonary or systemic circulation, from one arm to another, from arm to tongue, or from arm to lung; it is measured by the injection into an arm vein of a substance, such as sodium dehydrocholate, ether, fluorescein, histamine, or a radium salt, which can be detected when it arrives at another point in the vascular system.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • half time
    ¹ÝÀÏ ±Ù¹«;¹ÝÀϱÞ;(½ºÆ÷Ã÷)ÇÏÇÁ ŸÀÓ;Áß°£ ÈÞ½Ä
  • half time
    ¹ÝÀÏ ³ëµ¿;¹ÝÀϱÞ;Áß°£ ÈÞ½Ä
  • high time
    ÁÁÀº ¶§(½Ã±â);È£±â;Èï°Ü¿ï(À¯ÄèÇÑ)¶§
  • hold time
    (·ÎÄÏ,¹Ì»çÀÏ ¹ß»ç½ÃÀÇ ÃÊÀбâ,ÀÛ¾÷ µîÀÇ)ÀϽÃÀû Áß´Ü(´ë±â)
  • lap time
    ÇÑ ¹ÙÄû µµ´Â ½Ã°£;ÀÏÁֽð£
  • lead time
    ±âȹ¿¡¼­ »ý»ê±îÁöÀÇ ½Ã°£;¹ßÁÖ¿¡¼­ ¹è´Þ±îÁöÀÇ ½Ã°£;¹ßÁÖ¿¡¼­ ¹è´Þ±îÁöÀÇ ½Ã°£
  • local time
    Áö¹æ½Ã;ÇöÁö ½Ã°£
  • machine time
    (ÄÄÇ»ÅÍ µîÀÇ) ÃÑ ÀÛµ¿½Ã(°£);ÀÛµ¿ ¿¬½Ã°£
  • mean solar time
    Æò±Õ žç½Ã;Æò±Õ½Ã
  • monkey time
    ¼­¸Ó ŸÀÓ
  • mountain time
    »êÁö Ç¥ÁؽÃ
  • needle time
    (¿µ)(¹æ¼Û)·¹ÄÚµå À½¾Ç½Ã°£
  • oneline real time system
    Á÷°á ½Ç½Ã°£ ó¸® ¹æ½Ä
  • part time
    Á¤»ó(±Ù¹«)½Ã°£ÀÇ ÀϺÎ
  • post time
    ¿ìÆí ¹ß¼Û ½Ã°£;¿ìÆí Áý¹è ½Ã°£;·¹À̽º ÃâÀü ¿¹Á¤ ½Ã°£
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á